Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1111 to 1125 of 1242 results for public health guidance

  1. Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]

    Discontinued Reference number: GID-TA11034

    Technology appraisal guidance
    Discontinued

  2. Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]

    Discontinued Reference number: GID-TA11093

    Technology appraisal guidance
    Discontinued

  3. Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]

    In development Reference number: GID-TA11299 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]

    Discontinued Reference number: GID-TA11252

    Technology appraisal guidance
    Discontinued

  5. Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]

    In development Reference number: GID-TA11500 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]

    Discontinued Reference number: GID-TA11089

    Technology appraisal guidance
    Discontinued

  7. Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

    In development Reference number: GID-TA11281 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Botulinum toxin type A for preventing episodic migraine [ID6450]

    In development Reference number: GID-TA11505 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Nitazoxanide for treating the common cold in people 12 years and over [ID4049]

    Discontinued Reference number: GID-TA11128

    Technology appraisal guidance
    Discontinued

  10. Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]

    In development Reference number: GID-TA11586 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205]

    Discontinued Reference number: GID-TA10965

    Technology appraisal guidance
    Discontinued

  12. Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]

    In development Reference number: GID-TA11606 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]

    Discontinued Reference number: GID-TA11406

    Technology appraisal guidance
    Discontinued

  14. Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]

    Discontinued Reference number: GID-TA11033

    Technology appraisal guidance
    Discontinued

  15. Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica

    Discontinued Reference number: GID-IP2806

    Interventional procedures guidance
    Discontinued